Navigation Links
Novexel's NXL104/ceftazidime Combination Commences Phase II Clinical Trial in Hospital Patients With Complicated Urinary Tract Infections
Date:11/12/2008

pectrum includes class A (including ESBL and KPC) and class C enzymes. NXL104 in combination with ceftazidime will be targeting infections caused by Gram negative bacteria, including Enterobacteriaceae and Pseudomonas.

About Novexel

Novexel is a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance. The ever increasing resistance to marketed antibiotics has led to a clear need for novel drugs that are active against multi-drug resistant bacteria. Novexel's products are targeting the global hospital antibiotic market, which was worth an estimated $15bn in 2007 according to information derived from the IMS Midas(R) database.

Novexel currently has two novel antibacterials in Phase II clinical development. These are the injectable beta-lactamase inhibitor, NXL104, which is being developed in combination with the cephalosporin antibiotic ceftazidime for serious Gram negative infections, and the oral streptogramin antibiotic, NXL103, for the treatment of Gram positive infections, with a focus on treatment in the hospital setting and intravenous (IV) to oral switch. Novexel has three further programmes in preclinical development, NXL105, a novel anti-Pseudomonal antibiotic, NXL201, a novel echinocandin antifungal agent, and NXL104 in combination with ceftaroline. This latter product is being developed by our partner, Forest Laboratories, solely for North American markets.

Novexel was created in December 2004 as an independent spin-out of the sanofi-aventis (Euronext Paris: SAN, NYSE: SNY) anti-infectives unit. Novexel has a team of 50 employees with significant experience in anti-infective research and development, who are located in Paris, France and Philadelphia, USA.

---------------------------------

(i) USA: HCUPnet; France, Agence technique de l'Information sur

l'Hospitalisation ; UK The Informatio
'/>"/>

SOURCE Novexel
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
2. Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults
3. Vion Pharmaceuticals Enters into Agreement to Conduct a Phase I/II Clinical Trial of Cloretazine(R) in Combination with Induction Therapy in Poor Prognosis AML Patients
4. Micromet Presents Data at ESMO 2008 on Anti-EpCAM Antibody Adecatumumab (MT201) in Combination with Chemotherapy
5. Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma
6. Particle Sciences Expands Its Combination Product Capabilities
7. Vion Pharmaceuticals Enters Into Agreement With HOVON to Conduct a Phase III Clinical Trial of Cloretazine(R) in Combination With Frontline AML and MDS Therapy
8. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
10. Proteolix Initiates Phase 1b Clinical Trial of Carfilzomib in a Combination Regimen for Patients With Relapsed Multiple Myeloma
11. Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Oct. 21, 2014   BioNano Genomics , ... genomics research centers to purchase an Irys™ System ... National Cancer Institute (NCI), NIH Intramural Sequencing Center (NISC) ... Irys, obtaining a comprehensive view of a genome ... (NGS) does not deliver the scalability or reliability ...
(Date:10/22/2014)... 21, 2014 Abaxis, Inc. (NasdaqGS: ... analysis systems, today reported financial results for the second ... quarter overview: , Revenues of $53.9 million, up ... EPS of $0.24, up 33% over last year,s comparable ... from Abaxis Veterinary Reference Laboratories (AVRL) of $3.5 million, ...
(Date:10/22/2014)... WESTMINSTER, Colo. , Oct. 22, 2014   ... class of infusion systems designed to maximize targeted delivery ... is pleased to announce that oncologist John R. ... Norris Comprehensive Cancer Center, and surgical oncologist Steven ... Center have joined the Company,s Scientific Advisory Board (SAB).  ...
Breaking Medicine Technology:BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 2Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 4Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 5Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 6Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 7Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 8Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 9Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 10Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 11Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 12Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 13Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 14Surefire Medical's Scientific Advisory Board Expands, Broadens Clinical Trial Expertise 2
... 8 Mylan Inc. (Nasdaq: MYL ) today announced ... and license agreements with Wyeth, now part of Pfizer, relating ... 75 mg and 150 mg, the generic version of Wyeth,s ... Pursuant to the license agreement, Mylan will be granted a ...
... , BEVERLY ... pioneering medical opiate detoxification procedure, offers one of the ... technology to treat dependencies to Zolpidem, a prescription medication widely used ... including Ambien and Edluar. The Waismann Method of ...
Cached Medicine Technology:Mylan Announces Settlement Agreement Related to Antidepressant Effexor XR(R) 2Waismann Method Offers Safe and Alternative Treatment for Dependency to Ambien 2Waismann Method Offers Safe and Alternative Treatment for Dependency to Ambien 3
(Date:10/22/2014)... October 22, 2014 Lintelus, Inc., an ... Vice President of Sales, will be speaking on the ... Technology Expo on October 28, at the Holiday Inn ... a booth as well as a Tech Demo at ... can create a more engaging event experience. , The ...
(Date:10/22/2014)... Steven Reinberg HealthDay Reporter ... quickly add weight and length may be showing a genetic ... In adults, certain genes have been linked to increased body ... in fat and lean muscle, the researchers said. At ... taller. By ages 2 and 3, however, these genes were ...
(Date:10/22/2014)... Tara Haelle HealthDay Reporter ... among young adult men may lead to increased blood pressure, ... cause a similar rise in blood pressure for young adult ... when young adult women drank lightly or moderately, their risk ... found. "This finding parallels studies in older adult men ...
(Date:10/22/2014)... Dennis Thompson HealthDay Reporter , ... on Monday officially tightened guidelines for health workers treating Ebola ... and use of a respirator at all times. The ... the tougher rules after two Dallas nurses contracted Ebola while ... States, Liberian national Thomas Eric Duncan. Nina Pham is currently ...
(Date:10/20/2014)... With a mere 19 days to ... a brief fundraising stop at the  Law Offices ... from a debate last night with his opponent Gov. ... the first seven minutes because Crist had an electric ... incident in one word: "weird." , Before touching on ...
Breaking Medicine News(10 mins):Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 2Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 3
... , NEWPORT, Ky., June 4 Xanodyne Pharmaceuticals, Inc. ... been named to the position of President and Chief ... Company,s Board of Directors. In addition to Mr. Valentino,s ... led by MPM Capital. Current investors, participation also included; ...
... PARK, Calif., June 4 XTENT, Inc. (Nasdaq: ... from the United States Food and Drug Administration (FDA) for ... pivotal clinical program, composed of two pivotal trials called CUSTOM ... the United States of its Custom NX(R) Drug Eluting ...
... Cryobank , a leader in reproductive tissue banking, announced ... Reproductive Medicine Associates (RMA) of New ... collection center will provide fertility preservation services to patients in ... worldwide for outstanding donor semen services, California Cryobank also provides ...
... ... add new clinical rotations in obstetrics and gynecology at the Center for Haitian Studies ... ... University School of Medicine is pleased to announce it will add new clinical rotations ...
... ... Pediatric Gastroenterology Department published results from a promising yearlong study conducted ... reminder system to keep them taking critical medication on schedule. By ... only 2 patients experienced a rejection episode versus 12 patients prior ...
... ... Members for their service and selfless acts of courage that help make the IMD one ... ... District (IMD), the nation’s largest urban medical district, recognized its honored District Security Group (DSG) ...
Cached Medicine News:Health News:Xanodyne Announces New President/CEO and Completes $38 Million Equity Financing 2Health News:XTENT, Inc. Receives Conditional Approval for Investigational Device Exemption of Custom NX(R) Drug Eluting Stent System from United States Food and Drug Administration 2Health News:XTENT, Inc. Receives Conditional Approval for Investigational Device Exemption of Custom NX(R) Drug Eluting Stent System from United States Food and Drug Administration 3Health News:Leading Sperm Bank Expands Fertility Preservation Services to the Big Apple 2Health News:Ross University School of Medicine Expands Clinical Rotations in Miami 2Health News:Text Messaging Medication Reminders Significantly Reduces Organ Rejection in Pediatric Liver Transplant Recipients 2Health News:Text Messaging Medication Reminders Significantly Reduces Organ Rejection in Pediatric Liver Transplant Recipients 3Health News:Illinois Medical District Recognizes Officers of its District Security Group 2
... Wrist Fixator is now available in a ... necessary instrumentation. The surgical technique is printed ... reference. , ,This fixator allows the surgeon ... making multipaner adjustments in the frame via ...
... The WristJack External Fixation System for ... palmar tilt, radial inclination, length and rotation. ... to place the wrist into extension without ... are easily performed in the surgeons office. ...
... slender design contributes to overall low-profile frame ... The Connecting Clamp allows connection of 3.0 ... Uses 3.0 mm Carbon Fiber Rods. The ... to predrill and provide more stability and ...
The DFS MiniFixator is a lightweight, external device for the treatment of small bone fractures and osteotomies....
Medicine Products: